EUCTR2023-000944-46-Outside-EU/EEA进行中（未招募）1 期
A Phase IIa observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine against S. Typhimurium and S. Enteritidis, in adults, children and infants, including dose finding in infants, in Africa - INTS GMMA GVGH-004 (H04_03TP)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •All participants (adults, children, infants at 9 months of age and infants at 6 weeks of age) will be enrolled in the clinical site in Ghana and must satisfy ALL the following criteria at study entry:
- •Participants and/or participants' parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
- •Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
- •Healthy participants as established by medical history, clinical examination, and laboratory investigations.
- •Participants satisfying screening requirements.
- •Participants negative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
- •Adult participants must satisfy ALL the following criteria at study entry:
- •A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.
- •Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
- •Female participants of childbearing potential may be enrolled in the study if the participant:
- •- has practiced adequate contraception for 1 month prior to study intervention administration, and
- •- has a negative pregnancy test on the day of study intervention administration, and
- •- has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
- •Child participants must satisfy ALL the following criteria at study entry:
- •A male or female between and including 24 and 59 months of age at the time of the first study intervention administration.
- •Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR's.
- •Born after a gestation period of =37 weeks.
- •Infant participants must satisfy ALL the following criteria at study entry:
- •A male or female 6 weeks or 9 months of age at the time of the first study intervention administration.
- •Born after a gestation period of =37 weeks.
- •Born to a mother seronegative for HIV, hepatitis B virus and hepatitis C virus.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 496
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical conditions:
- •Known exposure to S. Typhimurium or S. Enteritidis during the period starting at birth for infants and children, and at 3 years for adults, as documented by patient records
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
- •Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study.
- •Progressive, unstable, or uncontrolled clinical conditions.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
- •Major congenital defects, as assessed by the investigator.
- •Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Acute disease and/or fever at the time of enrollment (fever is defined as temperature = 38.0°C).
- •Recurrent history or uncontrolled neurological disorders or seizures.
- •Any clinically significant hematological and/or biochemical laboratory abnormality.
- •Undernutrition defined as WHO Z-score less than -2 SD.
- •Malaria infection defined as the presence of asexual parasites in the blood.
- •Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
- •Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
- •Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- •Prior/Concomitant therapy:
- •History of receiving any investigational iNTS or GMMA vaccines in the participant's life.
- •Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions, or their planned use during the study period.
- •Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days before each dose and ending 28 days after the last dose of study interventions administration, with the exception of flu vaccines and vaccines administered as part of a public health vaccination campaign.
- •A vaccine not foreseen by the study protocol administered during the period starting at 14 days before the first dose and ending 14 days after the last dose of study interventions administration for live vaccines or 7 days in case of inactivated vaccines*, with the exception of flu vaccines or COVID-19 vaccine which may be considered on a case-by-case basis.
- •If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, provided it is used according to the local governmental recommendations and Sponsor is notified.
- •Under such circumstances, a participant may be considered eligible for study enrollment and/or study intervention administration after the appropriate window for delay has passed and inclusion/exclusion criteria have been re-checked, and if the participant is confirmed to be eligible.
- •Administration of long-acting immune-modifying drugs at any time during the study period.
- •Administration of immunoglobulins and/or any blood products or plasma derivatives from
研究者
相似试验
尚未招募
2 期
A study on the safety, reactogenicity, and immune response to the invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) vaccine against invasive nontyphoidal Salmonella in adults, children, and infantsInvasive nontyphoidal SalmonellaPaediatricsPACTR202305722094480GlaxoSmithKline Biologicals SA GSK516
进行中（未招募）
1 期
A study on the immune response and safety of various potencies of an investigational chickenpox vaccine compared with a marketed chickenpox vaccine, given to healthy children 12 to 15 months of ageImmunogenicity and safety of a varicella vaccine in healthy childrenMedDRA version: 21.1Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 100000004865EUCTR2022-001910-21-PLGlaxoSmithKline Biologicals SA (GSK)800
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months to 17 yearsMedDRA version: 9.1Level: LLTClassification code 10064097Term: Avian influenzaavian influenzaEUCTR2007-002480-27-FIovartis Vaccines and Diagnostics GmbH & Co. KG
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD-like Surface Antigen Adjuvanted with MF59C.1 Influenza Vaccines Containing 7.5 mg or 15 mg of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 mg of A/H5N1 Influenza Antigen, in Adults - NDActive influenza profilaxis pandemic strainMedDRA version: 8.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2006-004063-66-ITCHIRO
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two FLUAD-like Surface Antigen Adjuvanted with MF59C.1 Influenza Vaccines Containing 7.5 mcg or 15 mcg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects - NDActive influenza immunization pandemic strainsMedDRA version: 6.1Level: PTClassification code 10022000EUCTR2005-005871-14-ITCHIRO520